3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Adenocarcinoma, Follicular
1
Interventions
Magnetic Resonance Spectroscopy
15
lutetium Lu 177 dotatate
14
Specimen Handling
14
cabozantinib
10
Nivolumab
10
Everolimus
8
pembrolizumab
7
gallium Ga 68 dotatate
6
Ipilimumab
6
Cisplatin
5
Carboplatin
5
trametinib
4
olaparib
4
lenvatinib
4
X-Rays
4
Lutetium-177
4
Etoposide
4
Cyclophosphamide
4
CTLA-4 Antigen
4
fluorodopa F 18
3
fludarabine
3
dabrafenib
3
cemiplimab
3
Temozolomide
3
Phantoms, Imaging
3
Fluorodeoxyglucose F18
3
Blood Specimen Collection
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
selpercatinib
2
lanreotide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sodium Iodide
×
Endocrine
×
90 days
×
Clear all
NCT01398085
2026-05-07
IoN
University College, London
Phase 2/3
Active not recruiting
504 enrolled